CytoMed Therapeutics
Develops donor-derived and iPSC-based cell therapies for cancer.
Something off on this page? Send us feedback.
Profile
Develops off-the-shelf, donor-derived gamma-delta T-cell and iPSC-derived gamma-delta NKT therapies for cancer. Its early clinical lead and research-stage platforms have no product-sales revenue; potential future routes include approved-product commercialization, licensing, and partnering.
Develops allogeneic cancer cell therapies around donor-derived gamma-delta T cells and iPSC-derived gamma-delta natural-killer-T cells. CTM-N2D, the lead non-genetically modified candidate, uses healthy-donor cells expanded outside the body as an off-the-shelf investigational therapy in an early clinical study. Other platforms, including engineered-cell research, remain research or preclinical programs.
Runs research, process development, and manufacturing-related work across Singapore and Malaysia as a single research-and-development operation. With no approved product or product-sales revenue, potential commercial routes include approval-led commercialization, licensing, collaboration, and partnering. Trial progress depends on clinical proof, regulatory review, manufacturing consistency, licensed technology rights, liquidity, and continued Nasdaq-listing compliance.
Company facts
Key statistics
Year to date −33.8% · Average volume (30d) 149.9K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Sep 30, 2025Q2 FY25 | — | −$0.07 | — | — | $105.7K | — | +1.01% |
| Mar 31, 2025Q4 FY24 | — | −$0.05 | — | — | $74.3K | — | +0.92% |
| Sep 30, 2024Q2 FY24 | — | −$0.04 | — | — | $83.3K | — | +4.46% |
| Jun 30, 2024Q1 FY24 | — | −$0.05 | — | — | $61.0K | — | −3.85% |
Financial highlights
| 12 quarters | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | |
|---|---|---|---|---|---|---|---|
| Revenue | $111.2K | $56.2K | $105.7K | $105.8K | $160.9K | $131.8K | |
| Gross profit | $99.7K | $98.2K | $98.4K | $98.5K | $135.8K | −$436.0K | |
| Operating income | −$407.2K | −$1.3M | −$510.6K | −$511.2K | −$518.7K | −$1.8M | |
| Net income | −$568.8K | −$1.2M | −$882.3K | −$883.4K | −$681.3K | −$1.4M | |
| Diluted EPS | −$0.05 | −$0.10 | −$0.07 | −$0.07 | −$0.06 | −$0.11 | |
| Gross margin | 89.7% | 174.9% | 93.1% | 93.1% | 84.4% | -330.9% | |
| Operating margin | -366.3% | -2,348.7% | -483.0% | -483.0% | -322.4% | -1,403.1% |
Fiscal years (4-quarter sums)FY21 $33.0K · FY22 $185.4K · FY23 $318.3K · FY24 $343.4K · FY25 $504.2K
Balance sheet, Dec 31, 2025Cash & short-term investments $1.6M · Total debt $378.6K · Total assets $6.3M · Shareholders' equity $5.1M
Dividends
No dividends on record.
Ownership
Shares outstanding 11.83M · Float 3.49M · 29.5% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| mDR LTD | 1.31M | 11.33% | 13G | Mar 24, 2025 |
| 28 Consultants Ltd | 880.3K | 7.62% | 13G | Mar 4, 2025 |
| Chee Kong Choo · director, 10 percent owner: | 630.3K | 5.33% | Form 4 | Jul 24, 2026 |
| Yvonne Goh · officer: Chief Financial Officer | 25.8K | 0.22% | Form 4 | May 15, 2026 |
| Yoong Ying Tan · officer: Chief Corporate Officer | 25.8K | 0.22% | Form 4 | May 15, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 14, 2026 | Chee Kong Choo | director, 10 percent owner: | +200,000 | $1.50 |
| Jul 20, 2026 | Chee Kong Choo | director, 10 percent owner: | +200,000 | $1.50 |
| May 13, 2026 | Chee Kong Choo | director, 10 percent owner: | +112,000 | $1.15 |
Peers
- Adicet Bio
Allogeneic gamma-delta CAR-T platform in oncology.
- IN8bio
Gamma-delta T-cell programs in blood cancers and glioblastoma.
- Century Therapeutics
Renewable iPSC-derived allogeneic immune-cell platform.
- Fate
Off-the-shelf iPSC-derived CAR T and CAR NK platform.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| CytoMed Therapeutics | $0.9200 | 0.00% | $10.9M | — | — | 21.6 | +27.0% |
| Adicet Bio | $9.06 | +0.17% | $84.7M | — | — | — | — |
| IN8bio | $1.04 | +0.82% | $9.9M | — | — | — | — |
| Century Therapeutics | $2.03 | +0.25% | $175.3M | — | — | — | — |
| Fate | $2.43 | +0.60% | $283.2M | — | — | 43.6 | +9.2% |
| Median | — | — | 43.6 | +9.2% |